Alector Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Alector, Inc. (ALEC)
Last alector, inc. earnings: 3/24 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
Pivotal Phase 3 trial of AL001 initiated for treatment of frontotemporal dementia due to a progranulin gene mutation (FTD-GRN)Promising preliminary data from AL001 Phase 1b and Phase 2 open-label studies presented at Alzheimer’s Association International Conference AL002, AL003 and AL014 programs for the treatment of Alzheimer’s disease and AL101 neurology program continue to progressStrong cash and investments of $503.6 million to support execution of clinical, research and operational goals SOUTH SAN FRANCISCO, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced corporate updates and financial results for the second quarter ended June 30, 2020. “I am proud of the continued progress across our portfolio, most notably the initiation of our pivotal Phase 3 trial evaluating AL001 for the treatment of people with frontotemporal dementia,” said Arnon Rosenthal, Ph.D., co-founder and
Show less
Read more
Impact Snapshot
Event Time:
ALEC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALEC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALEC alerts
High impacting Alector, Inc. news events
Weekly update
A roundup of the hottest topics
ALEC
News
- Alector, Inc. (NASDAQ: ALEC) had its price target lowered by analysts at HC Wainwright from $41.00 to $35.00. They now have a "buy" rating on the stock.MarketBeat
- Alector, Inc. (NASDAQ: ALEC) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Alector to Participate in Upcoming Healthcare ConferencesGlobeNewswire
- Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Alector Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
ALEC
Earnings
- 5/8/24 - Beat
ALEC
Sec Filings
- 5/8/24 - Form 10-Q
- 5/8/24 - Form 8-K
- 5/2/24 - Form 4
- ALEC's page on the SEC website